By Josh Beckerman
Lifeward shares were higher as the medical device company received Food and Drug Administration 510(k) clearance for the ReWalk 7, the newest version of its personal exoskeleton product.
The stock was recently up 37% to $2.01, with an intraday range of $1.67 to $2.95. Volume was more than 95.5 million shares, compared with a 65-day average of 764,405.
The ReWalk is a motorized device that aids movement for some people with lower body paralysis.
Last week, Lifeward said full-year revenue rose to $25.7 million from $13.9 million. It said ReWalk Personal Exoskeleton sales increased by 130% in 2024, fueled by recently established Medicare coverage.
The company formerly known as ReWalk Robotics has been working to reduce operating losses, with moves including closing two U.S. facilities.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
March 13, 2025 12:58 ET (16:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。